Cryoablation Combined with Tislelizumab Plus Lenvatinib As Second-line or Later Therapy in Advanced Hepatocellular Carcinoma
Abroad (travel likely)RecruitingPHASE2
Conditions
Advanced Hepatocellular Carcinoma
Simple summaryAI-assisted
This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.
Locations
Fudan University Shanghai Cancer Center, Shanghai, Shanghai Municipality, China
Study leads
Peng Wang, MD
Principal Investigator
Fudan University